At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 228 enrolled
Drug / intervention
AZD1305 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, Placebo-controlled, Multicentre, Dose-escalating Study of AZD1305 Given Intravenously for Cardioversion of Atrial Fibrillation
In Brief
A Phase 2 clinical trial evaluating AZD1305 and Placebo for Atrial Fibrillation. Completed, enrolled 228 participants across 31 sites in 8 countries.
Detailed Summary
This study is being carried out to see which dose of AZD1305 is safe and effective in cardioverting atrial fibrillation into normal heart rhythm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesCzechia, Denmark, Hungary, Netherlands, Norway, Poland, Slovakia, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedJun 2009
Primary CompletionDec 2009
TodayJul 2026
First PostedJun 8, 2009
Enrollment StartMay 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.1 years ago
Interventions
AZD1305drug
Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Placebodrug
iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes